Lessons From Rosiglitazone

At a time when the clinical trials industry (and it has become an industry) is at the threshold of testing new complex clinical strategies for previously untreated conditions like Alzheimer's disease, we should be able to manage our research with intelligence and a sense of the primacy of our responsibility to patient care. It is critical to create an environment in which both patients and physicians believe that we are living up to those goals. The rosiglitazone saga leaves us far short of meeting that challenge.